- $1.48bn
- $2.27bn
- $1.37bn
Conmed Corp reports results for the quarter ended June 30 - Earnings Summary
Conmed Q2 sales, adjusted profit beat on organinc platform growth
Brief: Conmed Q2 Adjusted EPS USD 1.38 Vs. IBES Estimate USD 1.11
Brief: Conmed Is Said To Weigh Sale After Takeover Interest- Bloomberg News
Brief: Conmed Corporation Appoints John E. Gallagher As Chief Financial Officer
Brief: Conmed Enters Agreements To Repurchase 2.25% Convertible Senior Notes Due 2027 On June 3 - SEC Filing
Brief: Conmed Enters First Omnibus Amendment And Increased Facility Activation Notice On May 27, 2026 - SEC Filing
Brief: Conmed Corporation Appoints Celine Martin And Jeff Mirviss To Its Board Of Directors
Medical device maker Conmed raises 2026 organic rev outlook, reaffirms EPS guidance
Brief: Micro-Tech Endoscopy To Acquire Duraclip, Precisor, And Optibite Product Lines From CONMED
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
CONMED falls after Piper Sandler downgrades to 'neutral'
U.S. STOCKS ON THE MOVE-Elbit Systems, Oklo, Janus Henderson
U.S. STOCKS ON THE MOVE-Uber, Honeywell, Delta
Piper Sandler downgrades CONMED rating to 'neutral' on lack of catalysts
U.S. RESEARCH ROUNDUP-Amazon, Estée Lauder, Ralph Lauren
Conmed Q4 sales rise 7.9%, beat analyst estimates
Brief: Conmed Q4 Adjusted EPS USD 1.43 Vs. IBES Estimate USD 1.32